Feelings are running high in the UK pharmaceutical industry at the moment, with fears about a new NHS drugs budget squeeze and Brexit causing major concerns.
New rules on market access introduced by NICE from 1 April will affect most new medicines – but gaining access to ultra-orphan drugs could become much more difficult.
Pharma and patient groups are dismayed by new cost-capping and delaying measures, which they say will further restrict access to new medicines in England.
As the ASCO congress drew to a close, Johnson & Johnson filed for FDA approval of its BCMA-targeting CAR-T therapy Carvykti for use earlier in the treatment pathway fo
Health systems globally have reached a critical inflexion point, where ageing populations and tightening budgets mean we can no longer continue to purely treat late-stage symptomatic diseas